Published in Lab Business Week, June 11th, 2006
In conjunction with the planned portfolio realignment, the company recorded a goodwill impairment charge of $129.2 million, or $1.81 per share, for the Phase II-IV clinical business in the first quarter of 2006. As a result, the company reported a net loss per share of $1.40 for the first quarter of 2006, on sales of $283.8 million....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week